New Phase 3 Data Showed First-in-Class TREMFYA® (guselkumab) Provided Durable Complete Skin Clearance Through 5 Years in Moderate to Severe Plaque Psoriasis (Pso) and Robust Joint Improvement Through 52 Weeks in Active Psoriatic Arthritis (PsA)
- EMEA Innovative Medicine
- New Phase 3 Data Showed First-in-Class TREMFYA® (guselkumab) Provided Durable Complete Skin Clearance Through 5 Years in Moderate to Severe Plaque Psoriasis (Pso) and Robust Joint Improvement Through 52 Weeks in Active Psoriatic Arthritis (PsA)
New Phase 3 Data Showed First-in-Class TREMFYA® (guselkumab) Provided Durable Complete Skin Clearance Through 5 Years in Moderate to Severe Plaque Psoriasis (Pso) and Robust Joint Improvement Through 52 Weeks in Active Psoriatic Arthritis (PsA)
- X (Twitter)
Copy link